Aspiration & Biopsy Needles Market USD 1,272 Million By 2024, At A CAGR Of 7.3%
Seeking Alpha Analyst Since 2014
#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology
Summary
- The aspiration & biopsy needles market is estimated to grow at a CAGR of 7.3% to reach USD 1,272 Million by 2024 from USD 894 Million in 2019.
The aspiration & biopsy needles market is estimated to grow at a CAGR of 7.3% to reach USD 1,272 Million by 2024 from USD 894 Million in 2019.
Factors such as the rising prevalence of cancer, initiatives undertaken by government and global health organizations, and the increasing preference for minimally invasive procedures are the major factors driving the growth of the aspiration and biopsy needles market.
By site, the breast segment held the largest share of the market in 2019.
On the basis of site, the aspiration and biopsy needles market is segmented into breast, lung, colorectal, prostate, kidney, and bone & bone marrow. In 2019, the breast cancer segment accounted for the largest share of the market. The large share of this segment is mainly attributed to the rising prevalence of breast cancer, growing awareness about the disease, and increasing research activity pertaining to breast screening and diagnosis.
Download a PDF Brochure @ Aspiration & Biopsy Needles Market
Image-guided procedures accounted for the largest share of the aspiration and biopsy needles market, by procedure
On the basis of procedure, the aspiration and biopsy needles market is segmented into image-guided procedures (ultrasound-guided biopsy, stereotactic-guided biopsy, MRI-guided biopsy, and other image-guided procedures) and nonimage-guided procedures. Image-guided procedures accounted for the largest share of this market in 2018.
North America accounted for the largest share of the aspiration and biopsy needles market in 2019
This report covers the aspiration and biopsy needles market across four major geographies—North America, Europe, Asia Pacific, and the Rest of the World. North America commanded the largest share of the fine needle aspiration market in 2019. Factors such as the increasing prevalence of cancer in the US and Canada and cancer awareness initiatives undertaken by local governments and global health organizations in the North America region are the key factors driving market growth.
Request a Sample Pages @ Aspiration & Biopsy Needles Market
Key Market Players
CONMED Corporation (US), Medtronic Plc (Ireland), Olympus (Japan), Becton, Dickinson and Company (US), Boston Scientific Corporation (US), Cook Group Incorporated (US), Argon Medical Devices, Inc (US), INRAD Inc. (US), Somatex Medical Technologies (Germany), Stryker Corporation (US), Cardinal Health (US), Remington Medical (US), HAKKO CO.,LTD (Japan), and Merit Medical Systems (US)
Recent Developments
Product Launches and Approvals
- In September 2018, Olympus (Japan) received FDA approval for its EZ Shot Plus 25 G needle In April 2016, Olympus (Japan) launched aspiration biopsy needles with Side Port - Reusable (NA-2C-1)
- In November 2015, Cook Group (US) Incorporated launched EchoTip ProCore 20 Gage Needle for ultrasound-guided fine needle biopsy (FNB)
Acquisitions
- In January 2019, IZI Medical Products acquired Cook Medical’s soft tissue biopsy and breast localization needle product line.
- In February 2018, Merit Medical Systems, Inc. announced the closure of its purchase of divestment assets from BD (Becton, Dickinson and Company)
Speak to Analyst @ Aspiration & Biopsy Needles Market
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.